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CObjectives: A recent randomized trial demonstrated significant reduc-
tions in hemoglobin A1c levels with sensor-augmented pump therapy
SAPT) compared with multiple daily injections of insulin (MDI) in type
diabetes. We analyzed resource use in the trial and estimated the
ong-term cost-effectiveness of SAPT from the perspective of the US
ealth care system.Methods: Weundertook a cost-effectiveness anal-
sis combining estimates from the trial and the literature to populate
he previously validated Center for Outcomes Research (CORE) Diabe-
esModel. Results represent the use of 3-day sensors, as in the trial, and
-day sensors, approved in most markets but not yet approved in the
nited States. Results: Within-trial hospital days, emergency depart-
ent visits, and outpatient visits did not differ significantly between
he treatment groups. Assuming 65% use of 3-day sensors, treatment-
elated costs in year 1were an estimated $10,760 for SAPT and $5072 for
DI. Discounted lifetime estimates were $253,493 in direct medical
osts and 10.794 quality-adjusted life-years (QALYs) for SAPT and O
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oi:10.1016/j.jval.2012.02.011167,170 in direct medical costs and 10.418 QALYs for MDI. For 3-day
nd 6-day sensors, the incremental cost-effectiveness ratios were
229,675 per QALY (95% confidence interval $139,071–$720,865) and
168,104 per QALY (95% confidence interval $102,819–$523,161), re-
pectively. The ratios ranged from $69,837 to $211,113 per QALY with
ifferent strategies for incorporating utility benefits resulting from less
ear of hypoglycemia with SAPT. Conclusion: Despite superior clinical
enefits of SAPT compared with MDI, SAPT does not appear to be eco-
omically attractive in the United States for adults with type 1 diabetes
n its current state of development. However, further clinical develop-
ents reducing disposable costs of the system could significantly im-
rove its economic attractiveness.
eywords: insulin, type 1 diabetes mellitus.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Treatment to a target hemoglobin A1c (HbA1c) level of 7% or less
hrough an intensive insulin regimen can help patients with type
diabetes minimize or delay the incidence of complications asso-
iatedwith the disease [1,2]. Existing intensive treatments, includ-
ng continuous subcutaneous insulin infusion, are associatedwith
mproved glycemic control and fewer hypoglycemic events com-
aredwithmultiple daily injections of insulin (MDI) [3,4]. Improve-
ent in glycemic control may be related to accurate administra-
ion of rapid-acting insulin analogues at rates tailored to
ndividual patients’ needs [4]. Although insulin pumps and insulin
nalogues are available, achieving optimal glucose control re-
ains a challenge.
Continuous glucose monitoring (CGM), which uses a subcu-
aneous glucose sensor to measure interstitial glucose concen-
ration, has been shown to be more effective than standard
lucose monitoring in improving glycemic control, which leads
o lower glycated hemoglobin (i.e., HbA1c) levels [5]. The Sensor-
ugmented Pump Therapy for A1C Reduction (STAR 3) trial re-
ently compared sensor-augmented pump therapy (SAPT) with
Presented as a poster at the 16th Annual International Meetin
Research, May 24, 2011, Baltimore, MD.
† Dr Kamble is now with Quintiles, Rockville, MD.
* Address correspondence to: Shelby D. Reed, Duke Clinical Resea
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098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.DI among adults and children in the United States and Can-
da. SAPT combines insulin pump therapy and CGM in an inte-
rated system that allows monitoring through an Internet-
ased monitoring service. The STAR 3 trial demonstrated
uperior clinical outcomes with SAPT at 1 year, specifically re-
uctions in mean HbA1c levels [6].
Given the significant direct costs associatedwith initiation and
ongoing use of SAPT, it is important to evaluate its expected long-
term effects on costs and health outcomes compared with MDI.
We used data onmedical resource use collected during the STAR 3
trial to estimate the long-term cost-effectiveness of SAPT versus
MDI in adults with type 1 diabetes from the perspective of the US
health care system.
Methods
The design of STAR 3 has been described previously [7]. During the
52-week follow-up period, data on medical resource use were col-
lected at each study visit, including information on hospital ad-
missions, emergency department visits, and outpatient visits by
type of health care provider. Each visit was classified as related or
the International Society for Pharmacoeconomics and Outcomes
stitute, PO Box 17969, Durham, NC 27715.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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633V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 3 2 – 6 3 8unrelated to diabetes. In addition, the physicians, certified diabe-
tes educators, nurse practitioners, and registered nurses associ-
ated with the study reported the amount of time they spent with
patients for each study visit and for other activities, such as un-
scheduled visits, phone calls, and remote monitoring.
We valued provider time spent delivering diabetes-related care
by assigning an hourly rate corresponding to total compensation
(i.e., salary plus fringe) for each provider type [8]. During STAR 3,
3-day glucose sensors were provided to patients in the SAPT
group. By using information about the frequency of sensor use
(i.e., percentage of time) reported in STAR 3 [6], we calculated a
weighted average of 65% and estimated sensor costs on the basis
of this level of use. All costs are reported in 2010 US dollars. Ap-
pendix Table 1 in Supplemental Materials found at doi:10.1016/
j.jval.2012.02.011 shows the sources and assumptions we used to
estimate the annual costs of SAPT and MDI.
Computer simulation model for studies of long-term
cost-effectiveness
To extrapolate results from the clinical trial over the projected
remaining lifetime of the participants, we used the Center for Out-
comes Research (CORE) Diabetes Model version 7.0, a computer
simulationmodel validated for type 1 and type 2 diabetes through
66 internal and external validation analyses [9,10]. Themodel con-
sists of 15 submodels designed to simulate diabetes-related com-
plications, nonspecific mortality, and costs over time. Another
submodel simulates treatment changes for patients with type 2
diabetes who experience treatment failure or side effects. As the
model simulates patients over time, it updates risk factors and
complications to account for disease progression. The model can
account for the development of multiple diabetes-related compli-
cations simultaneously and for the interactive effect of one com-
plication on the risk of developing another. The model also ac-
counts for first-order (i.e., patient-level) and second-order (i.e.,
parameter-level) uncertainty to represent the degree of uncer-
tainty associated with the results of the cost-effectiveness analy-
sis. Probabilities of heart failure, myocardial infarction, and stroke
are based on data from the Framingham Heart Study or the UK
Prospective Diabetes Study, whichever is selected by the analyst
[9]. In this study, probabilities of heart failure and angina were
based on Framinghamdata and probabilities ofmyocardial infarc-
tion and stroke were based on data from the UK Prospective Dia-
betes Study.
Because the CORE Diabetes Model was developed from data for
adult patients, we restricted the long-term cost-effectiveness
analysis to adults. We evaluated the use of both the 3-day sensors
provided during the trial and the 6-day sensors currently available
in Canada, Australia, and Europe but not yet approved for market-
ing in the United States.
Data sources for the cost-effectiveness model
Patient characteristics and management
Baseline characteristics, including preventive and therapeutic
management strategies used in the CORE Diabetes Model, are
summarized inAppendix Table 2 in SupplementalMaterials found
at doi:10.1016/j.jval.2012.02.011. The primary source for the esti-
mates was the STAR 3 adult cohort (n 329) [6]. We assumed that
baseline characteristics were the same in both treatment arms.
We assumed that use of aspirin, statins, and angiotensin-convert-
ing enzyme inhibitors represented primary prevention of diabetes
complications, given themean age of the STAR 3 adult cohort (i.e.,
41 years) and the low rates of preexisting comorbid conditions. For
estimates not available from STAR 3, we relied on published
sources.Treatment effects
We used estimates of treatment effects in 329 adults from STAR 3.
These included a change from baseline HbA1c level (i.e., 8.3 per-
centage points in both the SAPT and MDI groups) of 1.0  0.7
percentage points for the SAPT group and 0.4  0.8 percentage
points for the MDI group at 1 year, a difference of0.6 percentage
points (95% confidence interval [CI]0.8 to0.4; P 0.001) in favor
f SAPT, with no changes in body mass index [6]. To model
hanges in HbA1c over time for both treatment arms, we applied
“table values” embedded in the CORE Diabetes Model, which rep-
resent HbA1c progression (i.e., increasing HbA1c levels) for type 1
diabetes based on the longitudinal changes observed in the Dia-
betes Control and Complications Trial [11]. The change in HbA1c
level is modeled as a linear change over time. With regard to
changes in body mass index, we applied the default option in the
CORE Diabetes Model representing no change in body mass index
over time. We used the Framingham progression approach for
changes in blood pressure and lipid levels.
Utilities
For health state utilities, we used the COREDiabetesModel default
values to maintain consistency with previous studies (see Appen-
dix Table 3 in Supplemental Materials found at doi:10.1016/j.
jval.2012.02.011) [9]. We assumed that the disutility for acute ke-
toacidosis was the same as for a major hypoglycemic event.
Costs
We used the costs of glucose meters and test strips, lancets, insu-
lin, and provider time to obtain annual treatment costs. For the
SAPT group, we also included costs of insulin pumps, transmit-
ters, sensors, insertion devices, and other pump supplies.We used
published estimates of insulin dose and annual use of glucose
meter test strips for both groups [4,12]. We reduced the costs of
insulin, devices, related supplies, and medications for diabetes
management by 16% [13] to represent lower prices paid by larger
private and public payers. Detailed cost estimates are shown in
Appendix Tables 1, 4, and 5 in Supplemental Materials found at
oi:10.1016/j.jval.2012.02.011.
Discounting
We applied a discount rate of 3% per year to costs and clinical
outcomes [14].
Time horizon
We applied a 60-year time horizon, consistent with previous stud-
ies [12,15–18]. This time horizon allows for development of all rel-
evant complications during the remainder of a patient’s lifetime.
Sensitivity analyses
We performed numerous sensitivity analyses to evaluate the im-
pact of varying model inputs and assumptions. Given the multi-
tude of sensitivity analyses performed, our reporting focuses on
those that we and others found to have the most impact on the
resulting cost-effectiveness ratios, including impact on HbA1c
level, fear of hypoglycemia, and scenarios that may better repre-
sent how SAPT is used in practice [18,19]. We varied the percent-
age use of sensors and the corresponding reduction inHbA1c levels
[6]. We also examined the impact of less frequent use of glucose
meter test strips in the SAPT group than in theMDI group (i.e., two
test strips per day as recommended for calibration [12], and two
fewer test strips per day than in the base case). To evaluate the
influence of potential technological advances, we ran the model
assuming that only one test strip would be required when the
sensor is replaced (i.e., one test strip every 3 days for a 3-day sen-
sor and every 6 days for a 6-day sensor).
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634 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 3 2 – 6 3 8In another set of sensitivity analyses, we evaluated the impact
of differences between the treatment groups on the Hypoglycemia
Fear Survey 98. The survey was administered during STAR 3 at
weeks 1, 13, 26, 39, and 52. Patients in the SAPT group reported an
improvement from baseline of 4.7 points (95% CI 2.5 to 6.9; P 
0.001), compared with the MDI group, on the “worry” subscale.
Therefore, we estimated the utility benefit associated with less
fear of hypoglycemia in the SAPT group from a separate study that
examined the independent relationship between the “worry” sub-
scale and the EuroQol five-dimensional questionnaire index (re-
gression coefficient0.007 [standard error 0.001]; P 0.001) from a
sample of 1305 patients with diabetes in the United Kingdom [20].
We applied the utility increment of 0.0329 (i.e., 4.7  0.007) to
he SAPT group in three ways. In approach 1, the utility increment
epresented an additive benefit in health-related quality of life
ith SAPT until patients experienced one or more complications.
eyond that point, we assigned the lowest corresponding utility
eight. In approach 2, we applied the utility increment through-
ut the remaining lifetimes of patients in the SAPT group, even
fter they experienced one or more complications. In approach 3,
e applied the utility increment to the first year of treatment in
he SAPT group.
Other sensitivity analyses included varying the annual costs of
APT by 20%, changing the baseline HbA1c level in the SAPT group
7], extending the replacement period for insulin pumps to 8 years
15–19, 21], reducing the hypoglycemia event rate in the SAPT
Table 1 – Within-trial estimates of medical resource use an
Resource
All-cause resource use
Hospital admissions, n (%)
0
1
2
3
Inpatient days, mean (SD)
Emergency department visits, n (%)
0
1
2
3
Outpatient visits, mean (SD)
Study site, mean (SD)
Nonstudy sites, mean (SD)
Diabetes-related resource use
Hospital admissions, n (%)
0
1‡
Inpatient days, mean (SD)
Emergency department visits, n (%)
0
1‡
Outpatient visits, mean (SD)
Study site, mean (SD)
Nonstudy sites, mean (SD)
Provider time for diabetes-related care (h), mean (SD)
Patient time for diabetes-related care (h), mean (SD)
MDI, multiple daily injections of insulin; NA, not available; SAPT, sen
* From Fisher exact test.
† From negative binomial test.
‡ Zero patients experienced more than one hospital admission or em
§ Not reported because of small numbers.
 From t test.roup, varying discount rates for costs and quality-adjusted life-ears (QALYs), choosing alternative sources to model progression
or blood pressure and lipid parameters, and doubling the direct
osts of complications. In addition, we adopted a societal perspec-
ive by incorporating patient time costs associated with treatment
nd days lost from work because of complications. Patients re-
orted the total amount of time per week spent on diabetes-re-
ated care throughout the trial. To estimate patient time costs, we
alued patient time spent on diabetes-related care on the basis of
ean wages [22]. The incremental cost-effectiveness ratios
ICERs) for sensitivity analyses were obtained from 1000 bootstrap
terations.
Results
Within-trial results
There were no significant differences between the treatment
groups in the proportions of adult patients who were hospitalized
or had one or more emergency department visits (Table 1). There
also were no significant differences in the mean number of inpa-
tient days or outpatient visits. During the 52-week trial, the total
mean time spent by providers and patients on diabetes-related
care was significantly higher in the SAPT group, a difference pri-
marily attributable to the greater investment of time in SAPT ini-
ovider and patient time.
SAPT
(n  166)
MDI
(n  163)
P
0.42*
155 (93.4) 155 (95.1)
7 (4.2) 8 (4.9)
2 (1.2) 0
2 (1.2) 0
0.5 (2.4) 0.2 (0.7) 0.14†
0.63*
136 (81.9) 139 (85.3)
27 (16.3) 21 (12.9)
3 (2.1) 2 (1.2)
0 1 (0.6)
0.5 (1.1) 0.4 (0.9) 0.18†
4.7 (8.4) 5.7 (9.8) 0.24†
0.50*
164 (98.8) 163 (100.0)
2 (1.2) 0
0.0 (0.4) 0 NA§
0.50*
160 (94.7) 160 (97.5)
6 (3.6) 3 (1.8)
0.4 (0.9) 0.3 (0.6) 0.08†
0.8 (1.6) 1.2 (2.8) 0.13†
15.0 (6.5) 6.4 (3.2) 0.001
20.1 (168.6) 166.1 (159.5) 0.003
ugmented pump therapy.
ncy department visit due to diabetes-related events.d pr
2
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ergetiation during the first few months.
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Incidence of complications
ImprovedHbA1c levels associatedwith SAPT led to lower predicted
ncidence of several microvascular complications over patients’
ifetimes. During the 60-year simulation period, the cumulative
ncidence of proliferative diabetic retinopathy and end-stage renal
isease decreased by 18.3% and 15.4% with SAPT versus MDI (see
ppendix Table 6 in Supplemental Materials found at doi:10.1016/
j.jval.2012.02.011).
Costs, QALYs, and incremental cost-effectiveness
With 3-day sensors, the discounted lifetime estimates of direct
medical costs and QALYs were $253,493 and 10.794 for SAPT and
$167,170 and 10.418 for MDI. The corresponding ICERwas $229,675
per QALY (95% CI $139,071–$720,865). With 6-day sensors, direct
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-100,000
-80,000
-60,000
-40,000
-20,000
0
20,000
40,000
60,000
80,000
100,000
120,000
-1.4 -1.2 -1 -0.8 -0.6 -0.4 -0
In
cr
em
en
ta
l C
os
ts
, U
S
$ 
20
10
Incre
3-day sensor, 65% usage
6-day sensor, 65% usage
Fig. 1 – Scatter plot of estimated joint density of 1000 bootst
Table 2 – Treatment costs and summary results for the bas
Outcome SAP
Treatment costs
3-d sensor
Cost of treatment, year 1 10,76
Cost of treatment, year 2 and beyond 10,25
6-d sensor
Cost of treatment, year 1 936
Cost of treatment, year 2 and beyond 885
Long-term direct costs and QALYs
SAPT with 3-d sensor
Discounted direct total costs ($), mean (SD) 253,493 (
Discounted QALYs (y), mean (SD) 10.794 (
Cost per QALY ($), mean (95% CI)
SAPT with 6-d sensor
Discounted direct total costs ($), mean (SD) 230,352 (
Discounted QALYs (y), mean (SD) 10.794 (
Cost per QALY ($), mean (95% CI)
CI, confidence interval; MDI, multiple daily injections of insulin; QALyears. QALYs, quality-adjusted life-years.medical costs were $230,352 for SAPT, or $168,104 per QALY (95%
CI $102,819– $523,161) (Table 2). A scatter plot representing the
estimated joint density of 1000 resampled estimates of incremen-
tal costs and QALYs is shown in Figure 1.
Sensitivity analyses
The largemajority of sensitivity analyses had relatively little impact
on the ICERs (Fig. 2; see Appendix Tables 7 and 8 in Supplemental
Materials found at doi:10.1016/j.jval.2012.02.011). However, varying
thenumberof glucosemeter test strips for SAPThadamarkedeffect.
With a 6-day sensor that requires one test strip per replacement for
calibration, the ICER decreased from $168,104 to $72,417 per QALY.
The ICERs ranged from$211,113 to $69,837 perQALYwhenwevaried
the utility benefit associated with less fear of hypoglycemia in the
SAPT group across three approaches (see Appendix Tables 7 and 8 in
upplemental Materials found at doi:10.1016/j.jval.2012.02.011).
0 0.2 0.4 0.6 0.8 1 1.2 1.4
l QALYs
$229,675/QALY
$168,104/QALY
eplications of incremental costs and quality-adjusted life-
se scenarios.
MDI Difference (SAPT – MDI)
5072 5689
4944 5311
5072 4293
4944 3915
167,170 (3058) 86,324 (4703)
) 10.418 (0.107) 0.376 (0.143)
229675 (139,071–720,865)
167,170 (3058) 63,182 (4583)
) 10.418 (0.107) 0.376 (0.143)
168,104 (102,819–523,161)
ality-adjusted life-year; SAPT, sensor-augmented pump therapy..2
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The relative improvement in HbA1c levels among adults in STAR 3
as 0.6 percentage points (1.0 vs. 0.4 percentage points; P 
.001) with SAPT comparedwithMDI at 1 year [6]. This benefit was
ot associatedwith short-termdifferences in hospital admissions,
mergency department visits, or outpatient visits. When we ex-
rapolated the trial results over a lifetime (i.e., 60 years), the incre-
ental cost-effectiveness of SAPT was an estimated $229,675 per
ALY with 3-day sensors and $168,104 per QALY with 6-day sen-
ors from the perspective of the US health care system.
To represent the use of 3-day sensors, we applied first-year
reatment costs of $10,760 for the SAPT group, compared with
5072 for the MDI group, a difference of $5689. In the second and
ubsequent years, we applied $10,255 for SAPT and $4944 for MDI,
difference of $5311. The major drivers of the incremental direct
ost were devices and supplies associated with SAPT, including
umps, sensors, transmitters, sensor insertion devices, reservoirs,
nd infusion sets ($6036 in year 1 for a 3-day sensor; see Appendix
able 1 in Supplemental Materials found at doi:10.1016/j.
jval.2012.02.011), while maintaining the confirmatory blood glu-
cose testing similar to patients in the MDI group. We tested key
assumptions in the CORE Diabetes Model by performing numer-
ous sensitivity analyses.With the technological advancement of a
sensor with a 6-day replacement period with 65% usage and re-
quiring only one test strip per replacement for calibration pur-
poses, the ICER for SAPT would improve dramatically to less than
$100,000 per QALY. It is likely, however, that the percentage use of
a 6-day sensor would be greater than 65%. Nevertheless, when we
increased the usage from 65% to 85% for a 6-day sensor with one
test strip per replacement, the ICER remained below $100,000 per
QALY.
When we incorporated the utility benefit of having less fear of
hypoglycemia with SAPT prior to the development of complica-
tions (“approach 1”) and then throughout remaining survival (“ap-
$0 $100,000 $200,000
Increase sensor use to 70%% (65% in base-case) and decrease
improvement in HbA1c to -0.79%-points (-1.0%-points in base-case) with
SAPT
Increase sensor use to 90%% (65% in base-case) and improvement in
HbA1c to -1.2%-points (-1.0%-points in base-case) with SAPT
Two-way Sensitivity Analyses
Apply utility benefit associated with less fear of hypoglycemia with SAPT
(Approach 3)
Apply utility benefit associated with less fear of hypoglycemia with SAPT
(Approach 2)
Apply utility benefit associated with less fear of hypoglycemia with SAPT
(Approach 1)
Vary change in HbA1c levels from -0.8% to -1.2%-points in SAPT arm
(1.0%-points in base-case)
Increase pump replacement period to 8 years (5 years in base-case)
Vary treatment costs for SAPT by ±20%
2 test strips per day with SAPT (5.75 per day in base-case)
1 test strip per sensor change with SAPT (5.75 per day in base-case)
Vary sensor use from 65% (base-case) to 45% and 85%
One-way Sensitivity Analyses
3-d
Fig. 2 – Summary results for sensitivity analyses. QALY, qua
etails regarding estimated costs and QALYs in each treatmen
found at doi:10.1016/j.jval.2012.02.011.proach 2”) (with 3-day sensors), the ICERs decreased from $229,675to $181,181 to $95,416 per QALY. With 6-day sensors, the corre-
sponding ICERs decreased from $168,104 to $132,611 to $69,837 per
QALY. When we limited the benefit to the first year of treatment
with SAPT (“approach 3”), there was relatively little change from
the base-case ICERs. These results imply that the value of SAPT
hinges on the handling of fear of hypoglycemia in the cost-effec-
tiveness analysis. Applying an additive utility benefit of 0.0329
across all health states experienced by patients in the SAPT group
is an optimistic scenario, suggesting that whatever diabetes-re-
lated complication patientsmay have incurred, they will continue
to accumulate QALYs at a higher rate with SAPT because of less
fear of hypoglycemia. Other studies that have evaluated utilities
associated with joint health states have found that the minimum
utility weight across health states best represents the utility of a
joint health state rather than an additive function of utility
weights [23,24]. Furthermore, patients in the SAPT group reported
less fear of hypoglycemia than did patients in the MDI group, de-
spite patients in the SAPT group having better glucose control,
though actual rates of severe hypoglycemiawere similar in STAR 3
(15.31 per 100 person-years with SAPT and 17.62 per 100 person-
years with MDI) [6].
The results of the STAR 3 cost-effectiveness analysis are not
directly comparable to the results of the recent Juvenile Diabetes
Research Foundation (JDRF) trial, which showed that CGM was
more effective than standard glucose monitoring in reducing
HbA1c levels (mean difference in HbA1c level change0.53; 95% CI
0.71 to 0.35; P  0.001) in adults 25 years and older with type 1
diabetes. However, the difference in HbA1c level change between
CGM and standard glucose monitoring was not significant among
patients aged 15 to 24 years (mean difference 0.08; 95% CI0.17 to
0.33; P  0.52) or among those aged 8 to 14 years (mean difference
0.13; 95% CI 0.38 to 0.11; P  0.29) [5]. The JDRF trial compared
the incremental value of CGM (i.e., sensor, transmitter, and re-
ceiver) with standard glucose monitoring. In that trial, more than
80% of patients in both treatment groups used insulin pumps at
,000 $400,000 $500,000
or  ($/QALY)   .
$0 $100,000 $200,000 $300,000 $400,000 $500,000
6-day Sensor ($/QALY)   
djusted life-year; SAPT, sensor-augmented pump therapy.
up are provided in Tables 6 and 7 in Supplemental Materials$300
ay Sens
lity-a
t grobaseline [12]. Thus, incremental direct costs in the JDRF study be-
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637V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 3 2 – 6 3 8tween the two groups represented additional costs with CGM rel-
ative to standard monitoring. In STAR 3, the incremental direct
cost represented additional costswith the combined use of insulin
pumps and CGM versus MDI with standard monitoring. In addi-
tion, long-term projections of costs and health outcomes in the
JDRF cost-effectiveness analysis were based on a newly developed
disease simulation model, whereas we used the CORE Diabetes
Model.
The ICERs in our study are significantly higher than those re-
ported in previous studies that used the CORE Diabetes Model to
evaluate the cost-effectiveness of pump therapy [17]. St Charles
et al. [17] applied annual direct costs of $5358 for continuous sub-
cutaneous insulin infusion, comparedwith $3776 forMDI, a differ-
ence of only $1582, and obtained an ICER of $16,992 per QALY. In
our analysis, higher incremental costs with SAPT were attribut-
able to sensors and transmitters needed for CGM and a higher cost
assigned to insulin pumps. If we had applied treatment costs from
St Charles et al. [17] in our study, the ICER would drop from
$229,675 to $63,198 perQALY. St Charles et al. [17] also applied a 1.2
percentage point decrease in HbA1c level with continuous subcu-
aneous insulin infusion versus MDI on the basis of a meta-anal-
sis of 52 studies published between 1979 and 2001, of which only
had a randomized parallel group design. If we applied a treat-
ent effect of this magnitude, the ICER would have decreased to
29,037 per QALY. Thus, the difference between the two studies is
ttributable to higher estimates of incremental treatment costs
nd lower estimates of relative effectiveness in our study based on
ctual data from STAR 3.
Our studyhas several limitations. First, to predict the incidence
f long-term complications of type 1 diabetes mellitus, the CORE
iabetes Model relies on data from the UK Prospective Diabetes
tudy, the Diabetes Control and Complications Trial, the Framing-
am Heart Study, and the Wisconsin Epidemiologic Study of Dia-
etic Retinopathy. Although these epidemiological data arewidely
sed to model health outcomes of patients with diabetes, they
ay not reflect progression of more recently diagnosed patients
ith type 1 diabetes treated in the modern era [25]. Second, out-
omes observed in clinical trials may not accurately reflect factors
uch as long-term adherence and varying standards of care that
ay influence costs and outcomes associated with diabetes.
hird, because 6-day sensors are not marketed in the United
tates, our analyses evaluating 6-day sensors assumed that the
ost per sensor would be the same as the cost per 3-day sensor.
imilarly, although we made assumptions in an attempt to most
ccurately reflect expected costs for diabetes devices and supplies
e.g., 16% discount, 65% sensor use), actual costs may differ across
atients, payers, and markets. There was also a slight difference
etween versions of the Hypoglycemia Fear Survey used to model
tility benefits associated with less fear of hypoglycemia [19] and
he version administered in STAR 3. The Hypoglycemia Fear Sur-
ey 98, rather than the original version, was administered in STAR
and includes an additional item in the “worry” subscale. Al-
hough we expect the impact on the incremental utility benefit to
e small, it introduces additional uncertainty into the analysis.
inally, patients in both treatment groups received a high level of
are and may have been particularly diligent with insulin therapy
iven their participation in the trial.
Conclusions
Data fromSTAR 3 demonstrated further reductions inHbA1c levels
mong patients receiving SAPT relative to MDI. The overall find-
ngs of our economic evaluation demonstrate that when consid-
ring the significant and ongoing costs associated with SAPT rel-
tive to MDI and costs of long-term complications in relation to
xpected health benefits, SAPT is not economically attractive over
number of scenarios for adult patients with type 1 diabetes. Aurprising finding from the sensitivity analyses was that subtle
ifferences in assumptions in the explicit modeling of patients’
ears about hypoglycemia can have a dramatic impact on the re-
ulting cost-effectiveness ratios. Our base-case results demon-
trate that replacing 3-day sensors with 6-day sensors without
er-unit price increases would improve the cost-effectiveness of
APT. The development of future technological advances that
ould allow for reduced use of glucose test strips with SAPT could
urther improve its economic attractiveness.
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